Search
BridgeBio Pharma Inc
BBIOAdd to Watchlist
81.070USD
-0.430-0.53%
Close 08-21 16:00（ET）
15.83BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-21The current earnings forecast score of BridgeBio Pharma Inc is 8.18, ranking 51 out of 155 in the Pharmaceuticals industry. The average price target is 82.00, with a high of 110.00 and a low of 42.21.
Analyst Rating
Based on
23
analysts
Buy
Current Rating
107.011
Target Price
+31.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
BridgeBio Pharma Inc
BBIO
23
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Regeneron Pharmaceuticals Inc
REGN
30
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is BridgeBio Pharma Inc's expected revenue for the next quarter?
BridgeBio Pharma Inc's expected revenue is 264.13M.
What is BridgeBio Pharma Inc's price target?
Analysts forecast that BridgeBio Pharma Inc's price target is USD 82.00, with the highest forecast at USD 110.00 and the lowest forecast at USD 42.21.
How have BridgeBio Pharma IncBBIO's recent earnings per share performed?
The market expectation was USD -0.78, while BridgeBio Pharma IncBBIO's earnings per share (EPS) for the previous quarter was USD -0.84. EPS for the next quarter is expected at USD -0.57.
What is the analyst rating for BridgeBio Pharma Inc?
Based on the ratings of BridgeBio Pharma Inc's stock from 23 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.